School of Medicine

Showing 1-8 of 8 Results

  • Mohsen Fathzadeh

    Mohsen Fathzadeh

    Postdoctoral Research Fellow, Cardiovascular Medicine

    Bio My long-term goal is to learn, develop and design frameworks to implement ?Precision Medicine? based on the ?rare? and ?common? genomic variants. Particularly, I am enthusiastic to construct global precision medicine basis to help individuals with diabetes, insulin resistance and cardiovascular comorbidity.
    After completing my master?s degree in human genetics, I was attracted by the fact that early onset coronary artery disease (CAD) manifest as a genetic subtype of the common type of CAD. In collaboration with Dr. Arya Mani and Dr. Richard Lifton, experts in Mendelian forms of CAD (Yale University), and Dr. Reza Malekzadeh, a pioneer of cohort studies (Tehran University), I contributed to the genetic analysis of families with early onset CAD and metabolic syndrome. We identified DYRK1B as a causative gene (co-first author; N Engl J Med; 2014).

    After completion of Ph.D. I was enthusiastic to be trained deeply on the genetic basis of diabetes and insulin resistance. Navigating through leading institutes, I found Stanford University an ideal place for this training; because here at Stanford Cardiovascular medicine, Dr. Gerald Reaven, a pioneer of insulin resistance, along with Drs. Thomas Quertermous and Joshua Knowles had developed the multicenter cohort for a GWAS of insulin resistance by direct measures of insulin sensitivity including ?clamp-based? measures of insulin resistance. This group had just identified and validated a common SNP (rs1208, 803A>G, K268R) in N-acetyltransferase 2 (NAT2) as insulin resistance variant. In this innovative training and career development, I am taking part in defining the role of Nat1 (mouse ortholog of NAT2) in the global and liver specific knockout mice. We have already profiled ?OMICs changes in the Nat1 global knockout mice with insulin resistance and extensively analyzed the data with promising finding on possible mechanism of mitochondria substrate availability and cholesterol biosynthesis.

    During postdoctoral fellowship, I have been involved in the joint project of Stanford-Merck on functional characterization of lipodystrophy-like genes identified through GWAS of glycemic traits (fasting insulin, HDL and WHR adjusted for BMI). This study has opened up new possibility and insight to target peripheral adiposity and insulin resistance. We extensively have been studying one of these promising targets in the transgenic mice and in the data from human cohorts.

  • Natalie Fischer

    Natalie Fischer

    Postdoctoral Research Fellow, Infectious Diseases

    Current Research and Scholarly Interests Studying the host-microbiome relationship in very early-onset inflammatory bowel disease via microbial DNA sequencing and analysis. Evaluating expression of antimicrobial peptides and other immune mediators in human stool via mass spectrometry in collaboration with the Elisa lab on campus. Another project focuses on the gut and skin microbiome in children with severe acute malnutrition in Bangladesh (in collaboration with Gary Darmstadt).

  • Douglas Franz, MD, MPH

    Douglas Franz, MD, MPH

    Postdoctoral Medical Fellow, Nephrology

    Bio Douglas Franz, MD, MPH is a board-eligable nephrologist and advanced geriatrics fellow with Veterans Affairs in Palo Alto and Stanford University. He enjoys taking care of patients with kidney disease and serving our veterans. Dr Franz has a particular interest in the management of kidney dysfunction in patients with advanced heart failure as well as in patients with peripheral vascular disease. He is training to further his skills in epidemiology and clinical research with the goal of becoming an independent investigator.

    Dr Franz is currently training for his first triathlon. He plays guitar, listens to books and podcasts, and enjoys spending time with his wife, daughter, and their wheaten terrier.

Footer Links:

Stanford Medicine Resources: